A global maternal group B streptococcus (GBS) vaccine would not only avert more than 20,000 early-onset cases of invasive disease in young infants and tens of thousands of deaths, but also provide substantial healthcare cost savings, according to a newly published study in PLOS Medicine.
The study was spearheaded by...
